Plate 05

Generalized Pustular Psoriasis

Also called: GPP · von Zumbusch psoriasis

Psoriasis
Illustration © Roxana Barin Click to enlarge

General information

  • Rare, severe, potentially life-threatening systemic inflammatory disease, now recognized as distinct from plaque psoriasis.
  • Characterized by macroscopically visible sterile pustules on erythematous skin, not restricted to acral areas or within psoriatic plaques.
  • Flares may develop rapidly over hours, with widespread superficial non-follicular pustules.
  • Pustules may coalesce into “lakes of pus.”
  • Systemic inflammation is common but is not required for diagnosis under recent international criteria.
  • May occur with or without previous plaque psoriasis.
  • The IL-36 pathway plays a major role in its pathogenesis.
  • Severe acute flares constitute a dermatologic emergency.

TRIGGERS

  • Abrupt systemic corticosteroid withdrawal +++.
  • Infections.
  • Medications.
  • Pregnancy - historically termed impetigo herpetiformis.
  • Hypocalcemia.
  • Physiological or psychological stress may contribute.
  • Some flares occur without an identifiable trigger.

Symptoms / presentation

  • Often rapid onset, sometimes within hours.
  • Painful erythema followed by numerous small superficial pustules.
  • Burning and skin tenderness/pain.
  • Fever, chills, fatigue, and malaise may occur.
  • Tachycardia, nausea, anorexia, or headache may accompany systemic inflammation.
  • Pustules subsequently dry with diffuse desquamation, while new crops may continue to develop.

COMPLICATIONS

  • Dehydration.
  • Electrolyte disturbances, including hypocalcemia.
  • Hypoalbuminemia.
  • Renal or hepatic dysfunction.
  • Temperature dysregulation.
  • Secondary bacterial infection and sepsis.
  • Pulmonary involvement.
  • Progression to erythroderma.

Clinical exam

  • Diffuse inflammatory erythema.
  • Numerous 2-3 mm superficial, non-follicular sterile pustules.
  • Pustules may coalesce into “lakes of pus.”
  • Subsequent diffuse scaling/desquamation.
  • Painful, tender skin.
  • Edema may occur.
  • Mucosal involvement may include cheilitis and geographic or fissured tongue.
  • Ocular involvement may include conjunctivitis, iritis, or uveitis.

Distribution

  • Diffuse inflammatory erythema.
  • Numerous 2–3 mm superficial, non-follicular sterile pustules.
  • Pustules may coalesce into “lakes of pus.”
  • Subsequent diffuse scaling/desquamation.
  • Painful, tender skin.
  • Edema may occur.
  • Mucosal involvement may include cheilitis and geographic or fissured tongue.
  • Ocular involvement may include conjunctivitis, iritis, or uveitis.

Dermoscopy

  • Homogeneous erythematous background.
  • Multiple superficial white-yellow pustules.
  • Dotted vessels may be visible.
  • White scaling during the desquamative phase.
  • Dermoscopy is adjunctive rather than required for diagnosis.

Diagnosis

  • Primarily clinical: macroscopically visible sterile pustules on erythematous skin, not restricted to acral sites or psoriatic plaques.
  • Skin biopsy when diagnosis is uncertain.
  • Histology: subcorneal neutrophilic pustules, spongiform pustules of Kogoj, parakeratosis ± Munro microabscesses.
  • CBC frequently demonstrates leukocytosis/neutrophilia.
  • CRP/ESR may be elevated.
  • Check electrolytes, calcium, renal/liver function, and albumin to assess systemic involvement.
  • Pustule culture when infection needs to be excluded.
  • Blood cultures when systemic infection/sepsis is suspected.

Differential diagnosis

  • Acute generalized exanthematous pustulosis (AGEP) +++.
  • Generalized bacterial pustular infection.
  • Subcorneal pustular dermatosis (Sneddon-Wilkinson disease).
  • IgA pemphigus.
  • Pemphigus foliaceus.
  • Dermatitis herpetiformis.
  • Other generalized pustular drug eruptions.

Treatment plan

  • Urgent dermatology assessment; hospitalization is usually required for significant acute flares.
  • IV fluids and correction of electrolyte abnormalities as required.
  • Monitor temperature, renal function, fluid balance, and hemodynamic status.
  • Bland emollients and supportive skin care.
  • Analgesia.
  • Antibiotics only for suspected or confirmed secondary infection.
  • Spesolimab, targeting the IL-36 receptor, is a GPP-specific targeted therapy that has changed contemporary management of acute GPP.
  • Other systemic options include cyclosporine, acitretin, methotrexate, and selected TNF-α, IL-17, or IL-23 biologics depending on clinical circumstances and availability.
  • Phototherapy is generally not practical for an acutely unstable flare but may have a role later in selected patients.
  • Pregnancy requires coordinated dermatology-obstetric management.

References

  1. DermNet. Generalised pustular psoriasis.
  2. Armstrong AW, et al. Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation. J Am Acad Dermatol. 2024;90(4):727–730.
  3. Puig L, et al. Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. J Eur Acad Dermatol Venereol. 2023;37(4):737–752.
  4. Navarini AA, et al. International Consensus Definition and Diagnostic Criteria for Generalized Pustular Psoriasis From the International Psoriasis Council. 2024.
  5. Bolognia JL, Schaffer JV, Cerroni L. Dermatology. Elsevier.